This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Colby TD , Vanderveen K , Strickler MD , Markham GD , Goldstein BM
Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design
Proceedings of the National Academy of Sciences of the United States of America. 1999 Mar 30;96(7) :3531-3536
AbstractInosine monophosphate dehydrogenase (IMPDH) controls a key metabolic step in the regulation of fell growth and differentiation. This step is the NAD-dependent oxidation of inosine 5' monophosphate (IMP) to xanthosine 5' monophosphate, the rate-limiting step in the synthesis of the guanine nucleotides. Two isoforms of IMPDH have been identified, one of which (type II) is significantly up- regulated in neoplastic and differentiating cells. As such, it has been identified as a major target in antitumor and immunosuppressive drug design. We present here the 2.9-Angstrom structure of a ternary complex of the human type II isoform of IMPDH. The complex contains the substrate analogue 6-chloropurine riboside 5'-monophosphate (6- Cl-IMP) and the NAD analogue selenazole-3-carboxamide adenine dinucleotide, the selenium derivative of the active metabolite of the antitumor drug tiazofurin. The enzyme forms a homotetramer, with the dinucleotide binding at the monomer- monomer interface. The 6 chloro-substituted purine base is dehalogenated, forming a covalent adduct at C6 with Cys-331. The dinucleotide selenazole base is stacked against the 6-Cl- IMP purine ring in an orientation consistent with the B-side stereochemistry of hydride transfer seen with NAD. The adenosine end of the ligand interacts with residues not conserved between the type I and type II isoforms, suggesting strategies for the design of isoform-specific agents.
NotesTimes Cited: 27 English Article 182PT PROC NAT ACAD SCI USA